- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) was delighted to meet recently with our Scientific Advisory Board in Sydney. We spent time working through details of our clinical trials for GDC-0084, our potential brain cancer therapeutic, and Cantrixil, our drug in development for ovarian cancer.
Stuart Roberts, Senior Analyst at NDF Research, took the opportunity to conduct wide-ranging interviews with each of the Scientific Advisory Board members, and Kazia plans to release these interviews over the next five weeks. The series provides rich and illuminating insight into how and why our Scientific Advisory Board are committed to our work of developing novel therapies for challenging diseases.
Professor Sir Murray Brennan is one of the world's most respected cancer surgeons and a global expert on soft tissue sarcoma.
In this excerpt of an interview led by Stuart Roberts, Senior Analyst with NDF Research, Sir Murray draws on his over 50 years of experience as a surgeon, oncologist, cancer researcher, and academic to provide a unique perspective on why new treatments for glioblastoma (brain cancer), such as Kazia’s drug GDC-0084, are needed alongside surgery to improve patient outcomes for what is a deadly and aggressive disease.
Along with his extensive experience in oncology research and overseeing blockbuster drugs to market, Professor Alex Matter is world-renowned for leading a team of scientists to discover and develop Gleevec (imatinib), one of the first targeted therapies for cancer.
In this interview, Professor Matter discusses his experience developing blockbuster drugs through to market, and shares his perspective on Kazia’s drug for glioblastoma, GDC-0084.
Dr Karen Ferrante is a haematologist-oncologist with over twenty years of experience in clinical oncology drug development, spanning both large pharmaceutical companies and fast-growing biotechs.
In this interview, Dr Ferrante shares her experience with drug regulatory bodies and her in-depth understanding about the drug approval process. She examines the context in which Kazia’s drug for glioblastoma, GDC-0084, is being developed, considering particularly that it has been granted Orphan Drug Designation by the US FDA.
In this first short video, we introduce you to SAB member Professor Peter Gunning, who is the head of the School of Medicine at the University of New South Wales, and head of the Oncology Research Unit. In the 1970s, he was one of the first researchers who started to look at the molecular architecture of cancer cells. This is an excerpt of the full video, which will be released at the end of the series.
In this interview, Professor Gunning talks about his career and shares what he finds most compelling about Kazia’s therapies which are currently undergoing clinical trials, GDC-0084 (for the most common and aggressive form of brain cancer, glioblastoma) and Cantrixil (for recurrent ovarian cancer).